Fortis Group Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.16M Sell
3,471
-38
-1% -$38.8K 0.67% 42
2026
Q1
$3.28M Sell
3,509
-36
-1% -$36.5K 0.54% 48
2025
Q4
$3.68M Buy
3,545
+414
+13% +$396K 0.62% 40
2025
Q3
$2.68M Buy
3,131
+781
+33% +$581K 0.46% 55
2025
Q2
$1.75M Sell
2,350
-343
-13% -$267K 0.32% 76
2025
Q1
$2.22M Sell
2,693
-72
-3% -$59.9K 0.43% 64
2024
Q4
$2.13M Sell
2,765
-1,630
-37% -$1.35M 0.4% 65
2024
Q3
$3.89M Sell
4,395
-192
-4% -$173K 0.72% 42
2024
Q2
$4.15M Buy
4,587
+1,973
+75% +$1.58M 0.82% 37
2024
Q1
$2.03M Buy
2,614
+2,214
+554% +$1.58M 0.37% 61
2023
Q4
$233K Buy
400
+200
+100% +$117K 0.06% 119
2023
Q3
$107K Buy
+200
New +$103K 0.03% 123
2020
Q3
$476K Buy
+3,221
New +$499K 0.09% 106

Other funds holding LLY

Fortis Group Advisors's LLY Position: Q2 2026 in Review

Fortis Group Advisors reduced its Eli Lilly (LLY) stake by 1.1% in Q2 2026, selling an estimated $38.8K and leaving 3,471 shares worth $4.16M. The position accounts for 0.67% of the portfolio, ranked #42.

Fortis Group Advisors first reported a position in LLY in Q3 2020 and has held it in 13 quarters since. 1,714 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Fortis Group Advisors held 3,471 shares of Eli Lilly worth $4.16M as of Q2 2026.
  • Fortis Group Advisors sold 38 Eli Lilly shares in Q2 2026, an estimated $38.8K.
  • Eli Lilly made up 0.67% of Fortis Group Advisors's portfolio in Q2 2026, its #42 holding.
  • Fortis Group Advisors first reported a position in Eli Lilly in Q3 2020 and has held it in 13 quarters since.
  • 1,714 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Fortis Group Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.